Morning Trend | BAO PHARMA-B experiences low-volume fluctuations, can the innovative drug concept bring new vitality?

Yesterday, the innovative drug sector performed moderately overall, with BAO PHARMA-B (2659.HK) maintaining a pattern of reduced volume consolidation. Throughout the day, market liquidity was limited, lacking significant signals of capital involvement. Influenced by news related to innovative drugs, there were occasional spikes during the trading session, but they quickly retreated. The company has no major announcements to drive momentum, and signs of main force positioning are not evident. From an industry perspective, the innovative drug direction is favored by capital in the medium to long term, but short-term hotspots are mostly focused on leading enterprises with news catalysts. BAO PHARMA lacks positive drivers, and its current premium capability is limited, with local rebounds primarily driven by short-term funds. The market is frequently adjusting positions, with funds mainly engaged in existing stock games. Major technical indicators are slightly strengthening at the margins, and bottom funds are tentatively testing, but the overall pattern leans towards a wait-and-see approach. Insufficient liquidity and dispersed main forces result in low volatility, and future performance still needs to pay attention to new news or sector movements. The inclination for flexible wave trading is increasing, and heavy position risks need to be continuously monitored. It is recommended to pay attention to news in the innovative drug industry and changes in company announcements. If positive catalysts appear, it may drive funds to re-enter